American Century Companies’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

American Century Companies’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-123,002	Closed	-$645K	–	2978
2024 Q1	$645K	Buy	123,002 +11,854	+11%	+$65.1K	﹤0.01%	2338
2023 Q4	$581K	Buy	111,148 +12,783	+13%	+$126K	﹤0.01%	2310
2023 Q3	$1.55M	Buy	98,365 +9,955	+11%	+$179K	﹤0.01%	1814
2023 Q2	$1.72M	Buy	88,410 +21,812	+33%	+$517K	﹤0.01%	1712
2023 Q1	$1.86M	Buy	66,598 +44,241	+198%	+$1.31M	﹤0.01%	1636
2022 Q4	$653K	Buy	+22,357	New	+$711K	﹤0.01%	1951
2022 Q1	–	Sell	-4,803	Closed	-$245K	–	2369
2021 Q4	$245K	Sell	4,803 -2,599	-35%	-$135K	﹤0.01%	2148
2021 Q3	$413K	Buy	+7,402	New	+$364K	﹤0.01%	1955
2021 Q1	–	Sell	-12,267	Closed	-$571K	–	2262
2020 Q4	$571K	Buy	12,267 +36	+0.3%	+$1.68K	﹤0.01%	1498
2020 Q3	$520K	Sell	12,231 -2,693	-18%	-$118K	﹤0.01%	1330
2020 Q2	$716K	Sell	14,924 -12,464	-46%	-$622K	﹤0.01%	1176
2020 Q1	$1.26M	Buy	27,388 +4,052	+17%	+$203K	﹤0.01%	942
2019 Q4	$1.4M	Sell	23,336 -31,324	-57%	-$1.87M	﹤0.01%	1028
2019 Q3	$3.09M	Buy	54,660 +567	+1%	+$31.9K	﹤0.01%	894
2019 Q2	$3.01M	Buy	+54,093	New	+$2.82M	﹤0.01%	948
2018 Q4	–	Sell	-3,215	Closed	-$223K	–	1360
2018 Q3	$223K	Buy	+3,215	New	+$244K	﹤0.01%	1231
2016 Q4	–	Sell	-27,425	Closed	-$1.92M	–	1421
2016 Q3	$1.92M	Sell	27,425 -87,476	-76%	-$4.85M	﹤0.01%	1062
2016 Q2	$4.46M	Buy	114,901 +6,567	+6%	+$273K	0.01%	868
2016 Q1	$4.39M	Sell	108,334 -13,186	-11%	-$837K	0.01%	853
2015 Q4	$10.8M	Buy	121,520 +55,842	+85%	+$4.41M	0.01%	621
2015 Q3	$4.86M	Buy	+65,678	New	+$5.46M	0.01%	839

Other funds holding EGRX

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

American Century Companies's EGRX Position: Q2 2024 in Review

American Century Companies sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2024, closing a stake of 123,002 shares — an estimated $645K sold.

American Century Companies first reported a position in EGRX in Q3 2015 and held it in 21 quarters. The position peaked at $10.8M in Q4 2015. 75 funds tracked by Wall St. Rank hold EGRX as of Q2 2024.

American Century Companies reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
American Century Companies sold 123,002 Eagle Pharmaceuticals, Inc. shares in Q2 2024, an estimated $645K.
American Century Companies first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2015 and held it in 21 quarters.
American Century Companies's Eagle Pharmaceuticals, Inc. position peaked at $10.8M in Q4 2015.
75 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2024.

Based on American Century Companies's 13F filing for Q2 2024, filed 7 Aug 2024.